EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A Thorough QT Study to Assess the Effects of Milvexian on Cardiac Repolarization in Healthy Participants

Peter Zannikos, JongHanne Park, Anna Dari, Samiha Takhtoukh, Paul Levesque, Alexei N Plotnikov, Amitava Mitra, Antoinette Ajavon-Hartmann, Samira Merali, Juan Jose Perez Ruixo, Navin Goyal

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.70015 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Peter Zannikos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Raritan, NJ, USA. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Milvexian is an oral factor XIa inhibitor in development for prevention of major thromboembolic conditions. This randomized, double‐blind, placebo‐ and positive‐controlled, multiple‐dose, four‐period crossover study assessed the cardic safety of milvexian (including effects on the QT interval of the electrocardiogram), with a supporting in vitro component. Sixty‐six participants were enrolled. In each treatment period, participants received milvexian (100 or 200 mg) or placebo every 12 h for 4 days. A single‐dose moxifloxacin (400 mg) served as a positive control. Electrocardiographs and time‐matched pharmacokinetic samples were collected during each period. In mixed‐effects models, the upper limit of the two‐sided 90% confidence interval for the least squares means for change from baseline QTc (Fridericia [QTcF], as the primary correction method) for milvexian versus placebo (ΔΔQTc) was ˂10 ms at all time points after each milvexian regimen. In addition, there was no apparent relationship between ΔΔQTcF and plasma milvexian concentrations. Moxifloxacin response confirmed assay sensitivity. Milvexian inhibited human ether‐a‐go‐go‐related gene potassium, sodium, and L‐type calcium ion channel currents with weak‐to‐moderate potency at concentrations exceeding the highest mean unbound maximum plasma concentrations of TQT study participants. Milvexian regimens were safe and well tolerated. These data indicate that milvexian does not prolong the QTc interval at clinically relevant concentrations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HumansDouble-Blind MethodCross-Over StudiesMaleFemaleAdultElectrocardiographyHealthy VolunteersYoung AdultMiddle AgedLong QT SyndromeMoxifloxacinHeart RateDose-Response Relationship, DrugPyrimidinesTriazoles

Stichwörter der Autor:innen

QTmilvexianpharmacokineticsrepolarizationsafety

Substanzen

MoxifloxacinmilvexianPyrimidinesTriazoles

Autor:innen und Institutionen

  • Johnson & Johnson, Raritan, NJ, USA.
  • Johnson & Johnson, Beerse, Belgium.
  • Bristol Myers Squibb, Princeton, NJ, USA.
  • Kura Oncology, Inc., Boston, MA, USA.

Zitieren

APA

Zannikos, P., Park, J., Dari, A., Takhtoukh, S., Levesque, P., Plotnikov, A. N., Mitra, A., Ajavon-Hartmann, A., Merali, S., Perez Ruixo, J. J., & Goyal, N. (2026). A Thorough QT Study to Assess the Effects of Milvexian on Cardiac Repolarization in Healthy Participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70015

Vancouver

Zannikos P, Park J, Dari A, Takhtoukh S, Levesque P, Plotnikov AN, et al. A Thorough QT Study to Assess the Effects of Milvexian on Cardiac Repolarization in Healthy Participants. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70015

BibTeX
@article{Zannikos2026,
  author = {Zannikos, Peter and Park, JongHanne and Dari, Anna and Takhtoukh, Samiha and Levesque, Paul and Plotnikov, Alexei N and Mitra, Amitava and Ajavon-Hartmann, Antoinette and Merali, Samira and Perez Ruixo, Juan Jose and Goyal, Navin},
  title = {A Thorough QT Study to Assess the Effects of Milvexian on Cardiac Repolarization in Healthy Participants},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.70015}
}
Kostenlos starten →